Genitourinary Review of Systems Related

Review Genitourinary Review of Systems related questions and content

Due to its potential for severe hepatoxicity, Nevirapine should NOT be * initiated in:

  • A. Women with CD4 cell counts >150 cells/mm3 or in men with CD4 cell count >400 cells/mm3
  • B. Women with CD4 cell counts >250 cells/mm3 or in men with CD4 cell count >400 cells/mm3
  • C. Women with CD4 cell counts >250 cells/mm3 or in men with CD4 cell count >500 cells/mm3
  • D. Women with CD4 cell counts >250 cells/mm3 or in men with CD4 cell count >450 cells/mm3
Correct Answer: D

Rationale: The correct answer is D because Nevirapine is associated with an increased risk of severe hepatoxicity, especially within the first few weeks of treatment initiation. The recommended CD4 cell count thresholds for starting Nevirapine are lower in women compared to men to minimize this risk. In this case, women with CD4 cell counts >250 cells/mm3 and men with CD4 cell counts >450 cells/mm3 should not initiate Nevirapine due to the higher likelihood of developing hepatoxicity.

A is incorrect because the CD4 cell count thresholds are too high for both women and men. B is incorrect as it sets the threshold for women too high. C is incorrect because the threshold for men is too high. Thus, D is the most appropriate choice based on the recommended guidelines to minimize the risk of severe hepatoxicity.